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Aim: To evaluate the role of endostatin (ES) gene therapy on myeloid-derived suppressor cells (MDSC) in a metastatic model 
of renal cell carcinoma (RCC). Materials and Methods: Balb/C mice bearing orthotopic Renca tumors were treated with NIH/3T3-
LendSN or, as a control, with NIH/3T3-LXSN cells. At the end of in vivo experiment, plasma and tissue lung samples were col-
lected. Plasma ES and granulocyte colony stimulating factor (G-CSF) levels were measured by ELISA and Milliplex, respectively. 
Quantification of CD11b+Gr-1+ cells and their subsets was performed by flow cytometry. Reactive oxygen species (ROS) production 
was measured in CD11b+Gr-1+ MDSC using the DCFDA marker by flow cytometry. Results: Metastatic RCC (mRCC) induced 
expansions of CD11b+Gr-1+ MDSC and promoted accumulation of these cells and their subtypes in lymphoid organ and metas-
tases. ES treatment promoted low G-CSF plasmatic levels which were produced by the tumor microenvironment, reflecting the 
reduced metastatic accumulation of CD11b+Gr-1+ MDSC in the lungs. However, the therapy was selective for granulocytic cells, 
thus reducing the production of ROS. Conclusion: These findings confirm the expansion of MDSC during metastatic progression 
of RCC and indicate the important role of ES in reducing MDSC and possible use of ES therapy in combined anticancer treatment.
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Renal cell carcinoma (RCC) is the most common 
neoplasm in the kidney [1]. The incidence of RCC 
has significantly increased over the past several 
years, mainly in North America and in the majority 
of Europe [2]. The American Cancer Society esti-
mates at least 62,700 new cases and approximately 
4,240 deaths in the United States for 2016 [1].
It is estimated that more than 30% of patients with 
RCC have metastatic disease at the time of diagno-
sis [3]. On the other hand, if diagnosed early, RCC 
is associated with a favorable prognosis of ~85% 
of a 5-year survival rate [4].
The most common histologic subtype of RCC 
is clear cell renal cell carcinoma (ccRCC), which rep-
resents 75% of parenchymal tumors. Moreover, some 
chromosomal abnormalities have been documented 
in ccRCC, including von Hippel — Lindau (VHL) mu-
tations on 3p25-26, 3p14.2 and 3p12 [5, 6]. In the 
majority of hereditary ccRCC tumors and in up to 92% 
of sporadic ccRCC tumors are associated with VHL 
gene defects in which the gene is inactivated [7]. The 
aggressive behavior of ccRCC is related to a VHL gene 
mutation that leads to stabilization of hypoxia-inducible 
factors (HIF-1α and HIF-2α) that in turn upregulates 
hypoxia-response genes, including vascular endothe-
lial growth factor (VEGF) [8].
The tumor microenvironment, composed of pa-
renchymal and stromal compartments, may release 
growth factors and cytokines to induce an immuno-
suppressive response [9]. These molecules contribute 
to the rapid recruitment, expansion and activation 
of several immunosuppressive cells, such as regula-
tory T cells (Tregs), tumor-associated macrophages 
(TAMs), type 2 natural killer T (NKT) cells, Tie2-
expressing monocytes, N2 neutrophils and myeloid-
derived suppressor cells (MDSC) [10]. Studies have 
correlated an increased number of MDSC in tumors 
with poor prognostic outcomes in patients with cancer. 
Although MDSC are one of the major contributors of tu-
mor-induced immunosuppression, they actively par-
ticipate in tumorigenic activities. These cells produce 
angiogenic factors, such as VEGF, basic fibroblast 
growth factor (bFGF), HIF-1, tumor growth factor beta 
(TGF-β) and matrix metalloprotease (MMP)-9, which 
are able to alter the environment to a pre-metastatic 
profile and promote neoangiogenesis [11].
MDSC are a major component of the immune 
suppressive network. In healthy individuals, immature 
myeloid cells (IMC) differentiate into macrophages, 
granulocytic and dendritic cells in bone marrow. 
In contrast, under various pathological conditions, 
such as cancer, a partial block of the differentiation 
of IMC leads to their expansion. These expanded IMC 
under pathological conditions are termed MDSC be-
cause of their immune suppressive properties. MDSC 
are composed by progenitor cells and IMC, which 
are identified in mice using the CD11b and Gr-1 mar-
kers [12–14].
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Notably, in cancer, MDSC are distributed among 
the primary and secondary lymphoid organs and the 
tumor site. Numerous tumor-secreted factors, includ-
ing cyclooxygenase 2, prostaglandins, stem-cell fac-
tor (SCF), monocyte-colony stimulate factor (M-CSF), 
interleukin-6 (IL-6), granulocyte/macrophage-colony 
stimulating factor (GM-CSF) and VEGF are known to in-
duce MDSC expansion and modify the myelopoiesis 
process. Furthermore, most of these factors can trig-
ger signaling pathways involving Janus kinase (JAK) 
protein family members and signal transducer and ac-
tivator of transcription 3 (STAT3) in MDSC, promoting 
cell survival, proliferation, reduced apoptosis and the 
prevention of the differentiation of myeloid progenitors 
into mature cells [10, 12].
However, two subsets have been identified within 
MDSC, namely granulocytic (G) or polymorphonu-
clear (PMN)-MDSC and monocytic or mononuclear 
(M)-MDSC. Based on the analyses of different tu-
mor experimental models, PMN-MDSC are the 
most predominant, representing at least 70–80% 
of MDSC. In addition, MDSC subsets distinctly induce 
suppressive mechanisms. The PMN-MDSC subset 
produces high levels of reactive oxygen and nitrogen 
species (ROS and RNS) and myeloperoxidase. In ad-
dition, peroxynitrite, a reactive nitrogen species, was 
also reported to be produced by PMN-MDSC. PMN-
MDSC suppress T-cell proliferation via a contact-
dependent and antigen-specific manner. This mecha-
nism induces nitrosylation or nitration of cysteine, 
methionine, tryptophan and primarily tyrosine that are 
present in T cell receptor (TCR)-CD8 complexes [15].
In contrast, M-MDSC trigger suppressive re-
sponses by producing high levels of inducible nitric 
oxide synthase (iNOS) and arginase 1 (Arg1). Both 
enzymes regulate the bioavailability of the amino acid 
L-arginine, which leads to a decrease in the CD3ζ-
chain, the production of interferon gamma (IFNγ) 
and interleukin-2 (IL-2) and an inhibition of T cell 
proliferation. These suppressive effects are mediated 
in an antigen-nonspecific manner [15, 16].
Therefore, strategies to target MDSC have led 
to new alternatives for improving antitumor therapies, 
including the deactivation or depletion of MDSC and 
their differentiation into mature myeloid cells. Never-
theless, a better understanding of the mechanism 
of MDSC expansion and activity may provide valuable 
information for future drug design.
Endostatin (ES) is a 20-KDa C-terminal fragment 
derived from collagen XVIII that was first purified 
from murine hemangioendothelioma and observed 
to exert in vivo and in vitro anti-tumor and antian-
giogenic activities [17]. The mechanisms involved 
in ES function have not been elucidated. Studies have 
described molecules of low or high-affinity that bind 
to ES, such as α5- and αv-integrins, glycopican-1 and 
glycopican-4 [18]. However, ES inhibits MMP-2 and 
promotes a blockade of VEGF/VEGFR signaling. 
Moreover, a genomic array analysis of human der-
mal microvascular endothelial cells after treatment 
with human recombinant ES showed its involvement 
in the downregulation of various genes associated 
with adhesion and matrix degradation, coagulation, 
apoptosis, angiogenesis and cell-cycle transition [19]. 
This protein was approved by the State Food Drug 
Administration (FDA) for the treatment of patients with 
non-small-cell lung cancer in China. Clinical trials have 
shown ES to be most effective when combined with 
other therapies, especially with chemotherapies [20]. 
This combination is believed to enhance its therapeutic 
efficacy and reduce side effects.
Recent studies have demonstrated that the use 
of chemotherapeutic drugs and antiangiogenic ty-
rosine kinase inhibitors lead to important biological 
effects in MDSC [21, 22].
In previous reports from our group, the antitumoral 
effects of ES resulted in an increase in survival rate 
and reductions in metastatic nodules and tumor area. 
However, a proinflammatory effect was confirmed 
based on the recruitment of effector cells to metastatic 
and secondary lymphoid sites and clonal expansion. 
Therefore, the efficacy of ES in this model has been 
shown to abrogate M2 expansion, favoring tumor 
elimination.
In this study, we evaluated the profile of myeloid 
cells in a metastatic renal cell carcinoma (mRCC) 
model and the ES effect on MDSC present in mRCC.
MATERIALS AND METHODS
Cell lines. Renca tumor cells were derived from 
a murine transplantable renal adenocarcinoma 
of spontaneous origin obtained from Cell Lines Ser-
vice (Eppelheim, DEU). These cells were maintained 
in RPMI 1640 medium from Life Technologies Corpora-
tion (Grand Island, NY, USA) supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 1% minimal Eagle’s medium nonessential 
amino acids, 100 U/ml penicillin, 100 �g/ml streptomy-
cin and 10% fetal bovine serum from Gibco-Invitrogen 
(Carlsbad, CA, USA).
NIH/3T3-LendSN-clone 5 and NIH 3T3-LXSN were 
used for ES expression and controls, respectively, 
as described previously [23]. Both cell lines were main-
tained with high-glucose-content (4.5 g/l at 25 mM) 
Dulbecco’s modified Eagle’s medium (DMEM) 
(Life Technologies Corporation) supplemented with 
100 U/ml penicillin, 100 �g/ml streptomycin and 10% 
fetal bovine serum (Gibco-Invitrogen, Carlsbad, CA, 
USA).
All cell lines were maintained in a humid chamber 
at 37 °C and under 5% carbon dioxide.
Animals.  Thir ty male Balb/c mice, aged 
8–10 weeks, were obtained from the Animal Facility 
of IPEN/CNEN-SP, São Paulo, Brazil. All animals were 
cared for in accordance with the standards of the 
Institute under a protocol approved by the Animal Ex-
perimentation Ethics Committee (Number of process: 
CEP 105/12).
Orthotopic mRCC model. Mice were anes-
thetized via intraperitoneal injection of ketamine 
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(100 mg/kg body weight, Ketalar; Parke-Davis, Morris 
Plains, NJ, USA) and xylazine (10 mg/kg body weight, 
Phoenix Scientific, Inc., St. Joseph, MO, USA). Renca 
cells (2•105) were inoculated into the renal subcapsu-
lar space, as previously described [23].
Seven days after Renca cell inoculation, the left 
kidney was removed via unilateral nephrectomy. The 
mice were divided into three groups (10 mice/group): 
control, metastasis and ES-treated.
Metastasis. At the end of experiment, all mice 
were exsanguinated and euthanized in accordance 
with the local institutional guidelines for animal care 
and approved by the University ethics committee. 
Healthy mice were used as organs and plasma donors 
for the normal group. The lungs from the group were 
excised and processed for analysis by flow cytometry.
ES gene therapy. On the day of nephrectomy, the 
control and ES-treated groups received subcutaneous 
injections of 3.6 x 106 NIH/3T3-LXSN and NIH/3T3-
LendSN-clone 5, respectively. After ten days, the lungs 
from the control and ES-treated groups were excised 
and processed for analysis by flow cytometry in vitro. 
A small pulmonary fragment was separated for fixing 
in methacarn for 3 h (containing 60% methanol, 30% 
chloroform and 10% glacial acetic acid) for hematoxy-
lin and eosin (HE) staining.
Histological analysis. Methacarn-fixed lungs 
were processed for paraffin embedding. Histological 
analysis was performed using 4-�m sections stained 
with HE, which were analyzed under a light micro-
scope. The images were obtained using a microscope 
(Leica DM1000, Leica Microsystems, Wetzlar, DEU), 
a digital compact camera (Leica DFC420C, Leica 
Microsystems) and an image processor (Leica Appli-
cation Suite v3.3.0). The quantification of metastatic 
lesions present in the pulmonary fragment was per-
formed by counting the lesions under a light micro-
scope at a 40x magnification.
Plasma ES levels were measured using a Mouse 
Endostatin ELISA Kit (Novateinbio® — Accelerates 
Research and Development — USA) according to the 
manufacturer’s instructions. The ES concentrations 
were determined at least in duplicate, and the assay 
reproducibility was confirmed. ELISA plates were read 
using the Multiskan EX Microplate Reader (Labsys-
tems, Milford, MA, USA) Plasma G-CSF levels were de-
termined using the Milliplex (Mouse Cytokine Magnetic 
Bead Panel, Millipore, Darmstadt, Germany), accord-
ing to the manufacturer’s instructions. The reading was 
made using a Luminex xMAP 100 system (Luminex 
Cooperation, Austin, Texas, USA), and the data were 
processed at the Xponent Software. The data were 
expressed as the mean fluorescence intensity (MIF).
Preparation of single-cell suspensions. Lungs 
were cut into smaller fragments (< 1 mm3) with sterile 
scissors, transferred to a beaker containing collage-
nase D at 2.5 mg/ml (Roche Diagnostics, Mannheim, 
DEU) diluted in RPMI 1640 and incubated for 30 min 
in a humid chamber at 37 °C under continuous agi-
tation. Next, 2 volumes of phosphate buffer saline 
(PBS) containing 0.5% fetal bovine serum and 0.5% 
EDTA at 0.5 M) were added, and then the cell sus-
pensions were filtered through a 70-�m cell strainer 
(BD Bioscience, San Jose, CA, USA). The tubes were 
centrifuged at 1500 rpm for 5 min, red blood cells were 
lysed using ammonium chloride lysis buffer (contain-
ing 0.155 M NH4Cl, 0.1 mM EDTA, 10 mM NaHCO3), 
and the tubes were supplemented with plant sterol 
esters (PSE) to make a total volume of 10 ml. Then, 
tubes were centrifuged, as described above, and the 
pellets were resuspended in 10 ml of PBS and main-
tained in ice.
Flow cytometry analysis. Single-cell suspensions 
from the lungs were seeded (106/well) in 96-well plates 
(“U” bottom), stained with allophycocyanin (APC)-
conjugated CD45.2 (Biolegend, San Diego, CA, USA), 
phicoerithrin (PE)-conjugated CD11b (eBioscience 
San Diego, CA, USA), phicoerithrin cyanin 7 (PE Cy7)-
conjugated Gr-1 (BD Bioscience, San Jose, CA, USA), 
peridinin chlorophyll 5.5 (PerCP Cy 5.5)-conjugated 
Ly6C and fluorescein isothiocyanate (FITC)-con-
jugated Ly6G antibodies (Biolegend) at a dilution 
1:100 in PSE, and then incubated for 25 min at 4 °C, 
protected from light. After washing with PBS, the plate 
was centrifuged at 1500 rpm for 5 min at 4 °C. The pel-
lets were resuspended in PBS, and immediately the 
plate was submitted to a BD Accuri C6 flow cytometer 
(BD Bioscience) to acquire 100,000 events in medium 
flow. The data were analyzed using FlowJo V10 Soft-
ware (Three Star Inc., Ashland, OR, USA). Gating 
strategy for flow cytometry was followed to quantify 
CD11b+Gr-1+ (R2), CD11b+Ly6ChighLy6G−/Monocytic 
(R4) and CD11b+ Ly6Clow Ly6G+ /Granulocytic (R5) 
cells (Fig. 1).
Isolation of Gr-1+ cells. Gr-1-positive cells were 
isolated using mouse Ly6G and Ly6C antibodies 
(BD Bioscience) and a BD ImagnetTM Cell Separa-
tion Magnet (BD Bioscience) following the manu-
facturer’s instructions. Gr-1+ cells were labelled with 
CD11b and Gr-1 antibodies, as described before. The 
purity of Gr-1+ populations was > 95%, as determined 
by flow cytometry. Giemsa staining of 104 Gr-1+ cells 
was performed to assess the polymorphonuclear and 
mononuclear morphology.
NO production. Gr-1+ cells (106/well) were seeded 
in 24-well plates containing 1 ml of RPMI 10% SFB me-
dium in the presence of LPS (Sigma-Aldrich, St Louis, 
MO, USA) at 1 �g/ml and incubated in a humid cham-
ber at 37 °C for 18 h. After incubation, the medium was 
collected and centrifuged at 1500 rpm for 5 min. The 
supernatant was added to 96-well plates to measure 
nitrite content using a colorimetric Nitrite/Nitrate as-
say kit (Cayman Chemical Company, Ann Arbor, MI, 
USA), following the manufacturer’s instructions. The 
absorbance at 540 nm was measured using a Multi-
skan X microplate plate reader.
Arginase assay. Gr-1+ cells (106) were resus-
pended in 60 �l lysis buffer containing EDTA at 0.1 mM, 
Tris HCl at 50 mM (pH 7.5) and protease inhibitors 
(Sigma-Aldrich) and then lysed by freeze-and-thaw 
Experimental Oncology 40, 24–32, 2018 (March) 27
cycles. The activity of arginase was determined from 
the urea production using the method described 
by Corraliza et al. [24]. The urea concentration was 
determined spectrophotometrically according to the 
absorbance at 550 nm measured using a Multiskan 
X microplate plate reader. The rate of urea production 
was used as an index for arginase activity.
The measurement of proteins for each sample 
(10 �l) was performed using a Nanodrop 2000 spec-
trophotometer (Thermo Fisher Scientific, Carlsbad, 
CA, USA), and then the ratio between of urea pro-
duction to protein concentration was calculated 
(�M urea/�g protein).
ROS production. Oxidation-sensitive dye DCFDA 
was used to measure ROS production. Gr-1+ cells 
(106) were labeled with 2.5 �M of CH-H2DCFDA 
(5-(and-6)-chloromethyl-2',7'-dichlorodihydroflu-
orescein diacetate, acetyl ester) (Thermo Fisher 
Scientific), following the manufacturer’s instructions. 
Next, cells were stained with APC CD45.2, PE CD11b, 
PE Cy7 Gr-1 PE antibodies, washed and centrifuged, 
as described before. The intensity of fluorescence 
was measured by flow cytometry and the data were 
expressed as median fluorescence intensity.
Statistical analysis. The data were analyzed and 
are expressed as the mean ± standard error (SE). 
Statistical analyses for single comparisons of mean 
values were performed using Student’s t-test, and 
multiple comparisons were performed using ANOVA 
followed by Bonferroni’s test in Graph pad prism ver-
sion 5.0 (Graph pad Software, San Diego, CA, USA), 
http://www.graphpad.com. The value of Probability (p) 
lower than 0.05 was considered statistically significant.
RESULTS
At the end of the experiment, ES plasma levels 
of normal group and experimental groups were mea-
sured. Normal group showed 119.3 ± 3.43 �g/ml, con-
trol group 215.02 ± 7.46 �g/ml and ES group 302.4 ± 
9.21 �g/ml. ES group had an increase of 2.53-fold the 
normal group (normal vs ES p < 0.001) and 1.40-fold 
compared to control (control vs ES p < 0.001). ES cir-
culating levels corroborated our previous data [23].
ES gene therapy promoted a reduction in meta-
static lesions and intratumoral CD11b+Gr-1+ 
cells. The CD11b+Gr-1+ cells and their subsets were 
assessed from metastatic lungs (Fig. 2). Initially, lung 
tissue sections were counted for the number of meta-
static lesions. The number of metastatic lesions in the 
lung parenchyma of the control group was 80 ± 8, 
whereas the ES-treated group exhibited a significant 
reduction to 30.0 ± 4.3 (p < 0.01) (Fig. 2, b).
The accumulation of CD11b+Gr-1+ cells on the 
metastatic lungs after ES treatment. Our data showed 
that the control group exhibited a 1.9-fold increase 
in the percentage of CD11b+Gr-1+ cells compared 
to the normal group. In contrast, ES-treated group 
Fig. 1. Gating strategy for flow cytometry analysis. In this sample gating, cells were first gated on granularity and size by SSC-
A vs FSC-A (P5), homogenous population for singlets by SSC-A vs SSC-H (P4), positive cells for CD45 (R1) and positive double for 
CD11b and Gr-1 (R2) for analysis of CD11b+Gr-1+ cells. To evaluate the monocytic and granulocytic cells, CD11b+ cells were gated 
(R3) and finally these populations were measured in CD11b+Ly6ChighLy6G− (R4) and CD11b+ Ly6ClowLy6G+ (R5) cells, respectively
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exhibited a 3.8-fold decrease in CD11b+Gr-1+ cells 
compared to the control group (p < 0.05) (Fig. 2, e).
ES impaired preferentially intratumoral granu-
locytic cells and decreased G-CSF plasma levels 
(Fig. 3). Monocytic cells population did not change 
in the lungs of ES-treated group (Fig. 3, b). On the 
other hand, granulocytic cells were more predominant 
in healthy lungs and were significantly reduced by 39% 
and 75.4% in the control (p < 0.01) and ES (p < 0.001) 
groups, respectively, compared to the normal group 
(Fig. 3, c). However, our data showed a significant 
difference of 9.1% in the number of granulocytic cells 
between the control and ES groups (p < 0.001).
To assess whether ES treatment interfered with 
cytokine and soluble factor plasma levels related to the 
prevalence of granulocytic cells, we measured the levels 
of granulocytes-colony stimulating factor (G-CSF) using 
the Milliplex. The control group was 12.1-fold higher 
than the normal group (p < 0.001), whereas treatment 
with ES reduced the levels by 2.9-fold compared to the 
control group the G-CSF levels (p < 0.05) (Fig. 3, d).
Gr-1+ cells purification and in vitro analysis. 
Previously, Gr-1+ cells were magnetically isolated 
from metastatic tumors of the lungs, stimulated with 
LPS (1 �g/ml), and the nitrite and cellular arginase 
activities were determined. Therefore, ROS-producing 
CD11b+Gr-1+ cells were quantified via flow cytometry. 
The purity of the Gr-1+ cells was approximately 97% 
(Fig. 4, a). Our data showed similar levels of nitrite 
in both the control and ES groups and undetected 
levels in the normal group (Fig. 4, b). On the other 
hand, arginase activity was reduced by 1.6-fold in the 
Fig. 2. Histopathological analysis of lung tissue sections by HE staining. Images captured observed in light microscopy at a 4× mag-
nification: a — experimental design; b — graphs expressing number of nodules mean counted in lung tissue from control and ES-
treated groups; d — quantification of CD11b+Gr-1+ cells (R2) in the metastatic lung after ES-treatment, representative dot plots (c) 
and graph expressing CD11b+Gr-1+ cells mean ± SEM; e — statistical analysis by Student’s test considering *p < 0.05 and **p < 0.01
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ES-treated group compared to the control group 
(p = 0.56) (Fig. 4, c). In contrast, ROS production was 
significantly reduced by 1.8-fold (Fig. 4, e).
DISCUSSION
Bone marrow-derived cells play important roles 
in tumor development. There are two major methods 
of vascular formation via vasculogenesis that involve 
endothelial progenitors and host inflammatory cells, 
such as macrophages and MDSC, which infiltrate tu-
mor tissues, alter the microenvironment, and promote 
tumor angiogenesis [14, 25–28]. Our data demo-
nstrated that kidneys containing tumors were able 
to recruit and accumulate intratumoral CD11b+Gr-1+ 
cells more than normal kidneys. This phenomenon has 
been demonstrated in patients with mRCC and could 
be explained by the production of soluble factors, 
such as VEGF, cytokines and proinflammatory sub-
stances [12, 15, 29–31]. Here, we detected monocytic 
cells into the tumor microenvironment, which supports 
the hypothesis that this subtype is able to tolerate 
hypoxic and acidic environments [32].
The tumor microenvironment is able to partially 
block the differentiation of IMC and, consequently, 
promote the expansion of immature cells in the bone 
marrow [10, 12, 15, 33, 34]. The data presented 
in this study demonstrated that CD11b+Gr-1+ cells, 
particularly the granulocytic subtype, were expanded 
Fig. 3. Quantification of monocytic (R4) and granulocytic (R5) cells in lung after treatment with ES. Representative dot plots, 
(a) graph expressing monocytic cells (R4) (b) and granulocytic cells (R5) mean. (c) Determination of plasma levels of soluble factor 
and cytokine measured by Milliplex. G-CSF (d) levels were determined in the plasma from normal, control and ES-treated groups. 
Statistical analysis by ANOVA followed by Bonferroni’s test considering *p < 0.05, **p < 0.01 and ***p < 0.001
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in bone marrow, which corroborates data reported 
in the literature [35–37]. The lymphoid organ is de-
scribed as a locale where PMN-MDSC cells mediate 
the antigen-specific suppressive mechanisms [12]. 
Our findings showed that the accumulation of splenic 
CD11b+Gr-1+ cells is directly associated with meta-
static progression of, preferentially, the granulocytic 
subtype on days 14 and 17.
Several pro-tumorigenic activities have been as-
sociated with the involvement of CD11b+Gr-1+ my-
eloid cells in the metastatic process, including the 
expression of proangiogenic factor Bv8, metastasis-
promoting lysil oxidase MMP-9 secretion, TGF-β-
mediated metastasis and immune tolerance and sup-
pression by virtue of MDSC activity [14, 38, 39]. Here, 
we identified that the accumulation of CD11b+Gr-1+ 
cells in metastatic lungs was inversely proportional 
to the metastatic process. Studies have revealed that 
CD11b+Gr-1+ cells change the pre-metastatic lung 
into an inflammatory and proliferative environment, 
promoting macrometastasis [39, 40]. In addition, 
advanced metastatic progression showed different 
sizes of metastatic lesions.
One of the most critical challenges in cancer treat-
ment is the absence of a functional immune system 
capable of efficiently controlling tumor development. 
However, most chemotherapeutic agents and radiation 
therapy also suppress the immune system. A selective 
panel of anticancer agents have been reported for 
their ability to selectively target immunosuppressive 
cells, such as Treg and MDSC, thereby enhancing the 
efficacy of immunotherapy [15, 41, 42].
Accordingly, we previously demonstrated that 
ES gene therapy elicits a pleotropic effect in the 
mRCC model, primarily as a potent pro-inflammatory 
and antitumor response, as observed on day 17 [43, 
44]. The production of ES by fibroblasts was 2.5-fold 
higher than that of non-producing fibroblasts, and 
the administration of these cells promoted a reduc-
tion in the metastatic foci number, corroborating our 
previous data [45].
Based on these findings, we hypothesize that 
ES gene therapy may also have the potential to reduce 
the number of CD11b+Gr-1+ cells, selectively targeting 
the granulocytic subtype. In addition, this effect was 
associated with a significant reduction in the level 
of circulating G-CSF. Additionally, high G-CSF levels 
have been reported in several tumor models and have 
been associated with increased expansion and recruit-
ment of granulocytic cells, inducing proangiogenic 
and immunosuppressive activities [46, 47]. However, 
cytokines present in the tumor microenvironment, 
such as IL-1β, were reduced after treatment with ES, 
suggesting an important role in myelopoiesis by gener-
ating MDSC [48]. These findings are contrary to those 
reported by Zhang et al. [49].
According to these observations, we analyzed the 
in vitro Gr-1+ cells obtained from the experimental 
groups and observed that the ES-treated group exhi-
bited reduced arginase activity and reduced produc-
tion of ROS associated with the antigen-specific immu-
nosuppressive mechanism used by granulocytic cells.
In this study, we provide, for the first time, the profile 
of CD11b+Gr-1+ cells in an orthotopic mRCC animal 
model and the effect of antiangiogenic gene therapy 
on these cells and their function. This report indicates 
that treatment with ES can be effective in modulat-
ing soluble factors for suppressing in the number 
of granulocytic cells and their function. Hence, our 
study highlights the use of ES as a regulator of the im-
Fig. 4. Functional analysis of magnetically Gr-1+ cells separated of lungs from normal, control and ES-treated groups. Dot plots 
showing strategy gating of delimited cells by SSC vs FSC (P5), homogenous population by SSC-A vs SSC-H (P4), CD45+ cells (R1) 
and positive double for CD11b and Gr-1 (R2) to evaluate the purity of Gr-1+ cells (a). Gr-1+ cells visualized in vitro and Giemsa stain-
ing showed these cells to have polymorphonuclear and monuclear morphologies (400× magnification) (b). Measurement of nitrite 
produced by LPS-stimulated Gr-1+ cells obtained of lungs (c). The cellular arginase activity of Gr-1+ cells stimulated with LPS for 
18 h (d) and median fluorescence intensity of the ROS production. (e) Statistical analysis by Student’s t-test and ANOVA followed 
by Bonferroni’s test considering. *p < 0.05
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munosuppressive response and as a promising target 
for use in combined therapies.
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